The main ingredients of Blinatumomab

Blinatumomab is a bispecific antibody designed to have dual affinity for specific cells. This antibody is widely used to treat acute lymphoblastic leukemia (ALL), specifically a subtype called B cell acute lymphoblastic leukemia (B-ALL). Here are details about the main ingredients of belintuzumab and how they work:

1.Antibody structure: The antibody structure of belintuzumab is composed of two different single-chain antibody fragments, one of which has a specific affinity and can bind to the B-ALL cell surfaceCD19antigen, while another fragment has specific affinity and can bind to the CD3antigen on the surface of T lymphocytes. The structure of this bispecific antibody allows it to precisely direct T cells to leukemia cells, enabling a highly targeted immunotherapy.

2.Mechanism of action: The bispecific antibody of belintuzumab can connect CD19 antigen and CD3antigen, and combine T lymphocytes with B-ALL cells. This connection leads to the activation of T cells, causing them to release cytotoxins that attack leukemia cells. This mechanism mimics a natural immune response, but in this case it is directed precisely at leukemia cells to reduce damage to healthy cells.

3.TargetingCD19: CD19 is a B cell surface antigen that is usually found on B-ALL cells. An antibody fragment of belintuzumab specifically binds to CD19, linking leukemia cells to T cells. This makesTThe cells can recognize and attackCD19positiveB-ALL cells, helping to reduce the number of leukemia cells.

4.TargetingCD3: Another antibody fragment of bellintumab specifically binds to the TCD3 antigen on the surface of T lymphocytes. In this way, the T cells are activated and directed to the vicinity of the leukemia cells, strengthening their interaction with the leukemia cells and increasing their attack power against the leukemia cells.

Belintuzumab can effectively guideT cells to leukemia cells through the mechanism of this bispecific antibody, prompting the immune system to strengthen its attack on leukemia cells. This treatment modality has achieved remarkable results in some patients with B-ALL and provides an important treatment option for those for whom traditional treatments are ineffective or unacceptable.